FDA report: Pfizer Inc (NYSE:PFE)’s Chantix causes more cardiovascular problem

An analysis of clinical trials revealed that the anti smoking medicine of Pfizer Inc (NYSE:PFE), Chantix, has caused a higher rate of heart attacks or strokes in patients using the treatment as compared to those  who didn’t take the drug.

It was stated by the FDA that the patients who were given Chantix and placebo showed different type of cardiovascular problem. It further stated that the increased risk wasn’t statistically major for those patients who used Chantix; it is observed that it is related to the medicine and not purely a chance finding.

Pfizer Inc (NYSE:PFE)’s anti smoking medicine Chantix carries a warning that it increases the chance of suicide and may cause higher heart danger in patients who are suffering from  cardiovascular problem.

The U.S. Food and Drug Administration said, among 4,190 Chantix users, 13 showed a major cardiovascular event such as heart attack or stroke in comparison with 6 of 2,812 who were treated with placebo in 15 Pfizer- sponsored clinical trials.

Pfizer Inc. (NYSE:PFE) total value after the recent close was $187.82 billion and the enterprise value according to yahoo data was $203.81billion. The previous 12 month price to sales ratio was 3.02. The company showed 15.69% as a profit margin in the last twelve months and an operating margin at 20.12%. Return on equity was 5.03% for the last twelve months. Return on assets was 5.03%.

Taking a look at some competitors, total value of Merck & Co., Inc. (NYSE:MRK) in the stock market was $137.59 billion and the takeover value of the company was $139.08 billion. The last twelve month price to sales ratio for the company was 2.85. It had a 14.41% as profit margin in the last twelve months and an operating margin at 18.79%. Return on assets was 6.48%.

The total value of Novartis AG (ADR) (NYSE:NVS) after the latest trading session was $152.95 billion and their enterprise value was $167.98 billion. The prior 52 week price to sales ratio was 2.66. The company recorded a profit margin of 15.21% for the prior 12 months and had an operating margin of 18.00%. Return on equity for this stock was 12.96% while return on assets appeared at 7.21%.

Sanofi SA (ADR) (NYSE:SNY) market capitalization after the most recent trading session was $15.30 billion and the enterprise value was $19.00 billion.